Progenitor Life Sciences of Salt Lake City, UT at MEDICA 2019 in Düsseldorf -- MEDICA - World Forum for Medicine
Manage stand orders
Select Option

Progenitor Life Sciences

675 Arapeen, Suite 302, 84108 Salt Lake City, UT
USA

This company is co-exhibitor of
Messe Düsseldorf North America

Hall map

MEDICA 2019 hall map (Hall 16): stand D27-1

Fairground map

MEDICA 2019 fairground map: Hall 16

Our range of products

Product categories

  • 03  Diagnostic Tests
  • 03.02  Immunochemistry testing, immunology testing
  • 03.02.01  Immuno assay testing

Our products

Product category: Immuno assay testing

Degas™ Receiver Cell Engineering

Progenitor DegasTM Receiver Cell Engineering Platform employs non-viral methods to introduce new DNA elements into specific genomic loci, such as so-called ‘safe-harbor sites’. Degas™ Cells are engineered to contain one or more landing pads that can be targeted for insertion of different DNA elements that impart new functions to cells (e.g., expression of cell surface receptors, transcription factors, suicide genes, etc.). Importantly, the DegasTM Platform enables development of isogenic cell lines that share identical genomes and differ only with regard to the DNA element inserted into the landing pad location. Hence, the Degas™ Platform enables parallel production of genetically identical lines that can be reliably compared to one another in functional screens, overcoming the problem of genetic drift that typically confounds production of cell lines by the usual approach of serial transfection, selection, and single-cell cloning.

More Less

Product category: Immuno assay testing

Van Gogh™ Footprint-Free Gene Editing

Progenitor Progenitor’s Van GoghTM Footprint-Free Gene Editing technology improves nuclease-based genetic engineering of immune cells by developing an efficient approach for removing unwanted selection cassette DNA. Van GoghTM Footprint-Free Gene Editing is a novel ‘self-excising’ cassette that enables rapid, permanent removal of the selection cassette by brief treatment of cells with a small molecule that induces Cre/loxP-mediated DNA recombination without possible reinsertion of deleted elements found in current gene editing market techniques. This technology ensures new levels of safety in constructs for cell immunotherapy.

More Less

Product category: Immuno assay testing

Kandinsky™ Survival Regulation

Progenitor Kandinsky™ Survival Regulation produces cells that require treatment with biologically and medically safe small molecules to maintain proliferation. For industrial applications, cell proliferation and survival can be controlled via specific additives in the media in which cells are maintained. For therapeutic applications, in vivo cell growth and proliferation and survival can be controlled by treatment of patients with medically safe, well-characterized, and well-tolerated compounds, enabling unprecedented control over induction, maintenance, and relapse phases of cell-based therapies. A unique feature of Kandinsky™ is that it employs an all-or-nothing regulation element that prevents genetic drift and development of resistance.

More Less

About us

Company details

Progenitor was born on the Matisse™ Reprogramming System technology for the generation of highly pluripoptent induced pluripotent stem cells. Using this technology, progenitor developed methods for immune cell differentiation, sparking their interest in the Cellular Immunotherapy.

Scientists have discovered new methods for cancer cell targeting using chimeric antigen receptor (CAR) constructs, that when paired with the body’s killing immune cells, can be a potent therapy for previously immuno-evasive cancers.

A major challenge for CAR-cell therapies in the clinic is their complexity and cost: present technology requires that primary immune cells be isolated and subjected to extensive in vitro engineering on a patient-by- patient basis, costing up to $500,000 per treatment per patient; hence routine clinical use of these therapies is potentially unfeasible in the current healthcare economy.

Seeing Immunotherapy’s need for an enhanced workflow, Progenitor set a goal to create IP for the generation of safer, economical and more advanced cellular therapeutics.

Through partnerships and collaborations, Progenitor has created a novel workflow covering all aspects of cellular therapeutic generation. Using next generation CAR constructs, gene editing techniques and “Off-the-shelf” approaches, Progenitor is enabling the future of Immunotherapies.
 
 
 

More Less